Patent Law Weblog
recent posts
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs – Part II
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
about
Month: July 2009
-
July 20, 2009 – Buying, Selling and Licensing Patents: Strategies for Turning Your Patent Portfolios into Revenue Streams (Law Seminars International) – Washington, DC July 21-22, 2009 – FDA Boot Camp*** (American Conference Institute) – Chicago, IL July 23-24, 2009 – Advanced Patent Prosecution Workshop 2009: Claim Drafting & Amendment Writing (Practising Law Institute) –…
-
The 2009 World Stem Cell Summit will be taking place on September 21-22 in Baltimore, MD. The 2009 Summit, which is being organized in part by the Genetics Policy Institute, will bring together researchers, clinicians, business pathfinders, key policy-makers, regulators, advocates, and experts in law and ethics to give presentations, share information, and chart the…
-
The Intellectual Property Owners Association (IPO) will be holding its 2009 Annual Meeting on September 13-15, 2009 in Chicago, IL. Among the presentations being offered at the annual meeting are: • Building, protecting and getting the most out of your IP portfolio in today's economic climate: A New quality-and-cost paradigm;• Remedies: Damages and injunctive relief…
-
Practising Law Institute (PLI) will be holding a seminar on Developments in Pharmaceutical and Biotech Patent Law on September 17, 2009 in New York, NY and on October 14, 2009 in San Francisco, CA. Groupcasts of the New York session will also be held in Boston, MA; Philadelphia, PA; Pittsburgh, PA; and New Brunswick, NJ. …
-
By Donald Zuhn — In a hearing on follow-on biologics held earlier this week, the House Subcommittee on the Courts and Competition Policy heard testimony from seven witnesses including Rep. Anna Eshoo (D-CA), economist Alex Brill, Momenta Pharmaceuticals General Counsel Bruce Leicher, and representatives from the National Venture Capital Association (NVCA), Biotechnology Industry Organization…
-
By Kevin E. Noonan — Follow-on biologic drugs, or biosimilars as they are called in Europe, are once again the subject of attempts by Congress to provide a regulatory pathway for approval. Currently, these drugs are not regulated by the Food, Drug and Cosmetic Act and hence not subject to the provisions of the…
-
By Donald Zuhn — This afternoon, the House Subcommittee on the Courts and Competition Policy held a hearing on follow-on biologics entitled "Biologics and Biosimilars: Balancing Incentives for Innovation." Among the witnesses appearing before the Subcommittee were Rep. Anna Eshoo (D-CA), who introduced follow-on biologics legislation (H.R. 1548) in the House that would provide…
-
By Suresh Pillai — Settlement Announced in Eloxatin® Suit The U.S. District Court for the District of New Jersey has issued an order announcing a settlement of all outstanding litigation between Sanofi-Aventis and Ebewe Pharma over Eloxatin®, a colon cancer drug marketed and distributed by Sanofi. This settlement puts an end to two years…
-
By Kevin E. Noonan — As reported today in The Wall Street Journal, the innovator biotechnology industry scored a major victory in the Senate on Monday, when that chamber's Health, Education, Labor and Pensions Committee approved an amendment providing a 12-year data exclusivity period for biologic drug makers. The committee voted 16-7 in favor…
-
By Donald Zuhn — On Friday, the National Venture Capital Association (NVCA) released the results of a study suggesting that "a data exclusivity period of at least 12 years for innovator products is a critical fulcrum in the effort to balance cost with the preservation of biotech innovation." The results of the NVCA-commissioned study…
Patent Docs 